poster
Biological activity of mRNA drugs, historically assessed via animal study, is critical to drug development, mechanistic evaluation of drug candidates, and as a manufacturing critical quality attribute (CQA). However, animal testing is costly, time-consuming and presents a significant environmental impact highlighted by the recent passing of Bill S.5002 - FDA Modernization Act 2.0 which aims to mediate the ecological impact of drug discovery and development by reducing animal use. The aim of this study is to develop quantitative assessment of mRNA drug biological activity by cell-based Assays.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.